Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

424.52 -8.51 (-1.97%)
Delayed Quote Updated: 12:38 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Kaplan Fox is Investigating Potential Securities Law Violations Against Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Kaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Investigation of Possible Securities Law Violations
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
MADRIGAL PHARMACEUTICALS, INC. MDGL INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 8.1% Share Drop
From Kirby McInerney LLP
Via Business Wire
News headline image
Kaplan Fox Notifies Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) of an Investigation Into Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Q2 Beat Yet Shares Slide on Rezdiffra Ramp Worries ↗
Via Chartmill
News headline image
NASDAQ: MDGL Investigation: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, PA - November 10, 2026 (NEWMEDIAWIRE) - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the... 
Via NewMediaWire
Topics Whistleblower
News headline image
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations Investors are Encouraged to Contact the Firm
NEW YORK, NY - November 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ:... 
Via NewMediaWire
News headline image
Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law Violations
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Whistleblower
News headline image
Madrigal Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Madrigal Pharmaceuticals (MDGL)
From Levi &amp; Korsinsky, LLP
Via ACCESS Newswire
News headline image
MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Kaplan Fox Announces an Investigation Into Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
Lost Money on Madrigal Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 8.1% Share Price Drop
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Did You Lose Money on Madrigal Pharmaceuticals, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 8.1% Share Price Decline
From The Law Offices of Howard G. Smith
Via Business Wire
News headline image
Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Possible Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Lost Money on Madrigal Pharmaceuticals, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 8.1% Stock Decline
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Kaplan Fox & Kilsheimer LLP Encourages Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding Potential Securities Law Violations
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
Madrigal (MDGL) Q3 2026 Earnings Call Transcript ↗
Rezdiffra hits blockbuster status as net income turns positive for first time. 
Via The Motley Fool
Topics Earnings
News headline image
What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Call ↗
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported third-quarter 2026 net sales of $431.3 million for its MASH treatment Rezdiffra, up 50% from the prior-year period, as the company said it continued to... 
Via MarketBeat
Topics Earnings
News headline image
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? ↗
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease. 
Via The Motley Fool
News headline image
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off ↗
Rezdiffra's biggest growth opportunity may still be ahead. 
Via The Motley Fool
News headline image
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands ↗
Madrigal Pharmaceuticals (NASDAQ:MDGL) said Rezdiffra continued to post strong commercial growth in the second quarter of 2026, while the company expanded its development pipeline around the MASH... 
Via MarketBeat
News headline image
Madrigal Pharmaceuticals Q2 Earnings Call Highlights ↗
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported second-quarter 2026 net sales of $364.3 million for Rezdiffra, up 71% from a year earlier, as the company continued to expand the number of patients... 
Via MarketBeat
Topics Earnings
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
Sometimes, little-known stocks are worth buying. 
Via The Motley Fool
News headline image
3 Under-the-Radar Stocks to Buy and Hold for a Decade ↗
All three could become highly prominent biotech companies within 10 years. 
Via The Motley Fool
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.